scholarly journals QUALIDADE DE VIDA DO PACIENTE COMI NSUFICIÊNCIA RENAL CRÔNICA SUBMETIDO À HEMODIÁLISE

2018 ◽  
pp. 32-36
Author(s):  
Elaine Cristina Negri ◽  
Ana Caroline de Lima Sampaio ◽  
Ana Cláudia Pereira da Silva ◽  
Helora Martines Paulo ◽  
Leandro Borsari da Costa ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Data Analysis ◽  
Kidney Disease ◽  
Mortality Rate ◽  
Social Welfare ◽  
Life Quality ◽  
High Morbidity ◽  
Hemodialysis Treatment ◽  
Research Goal ◽  
Main Factors

The chronic kidney disease is multicausal condition with high morbidity and mortality rate, thathas hemodialysis as the main option of treatment. Life quality is a large term which includes physical, psychological and social welfare that is related with happiness perception when compared to external aspects. The research goal wasto rate the welfareof patients with chronic kidney disease that undergoes hemodialysis treatment. The research was made with 63 patients who filled two formularies: one of themabout sample characterizationand instrument WHOQOL-bref made by 26 questions. The data analysis shows that among the analyzed areas, the physical domainhas got the lowest score which may be one of the main factors that influences the welfare.

scholarly journals Differences in the quality of life of chronic kidney disease patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis

2021 ◽  
Vol 10 (2) ◽  
Author(s):  
Ika Setyo Rini ◽  
Titik Rahmayani ◽  
Efris Kartika Sari ◽  
Retno Lestari
Keyword(s):  
Quality Of Life ◽  
Chronic Kidney Disease ◽  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Life Quality ◽  
P Value ◽  
Minimal Amount ◽  
Cross Sectional

Background: Chronic kidney disease (CKD) is defined as a progressive disease that causes renal failure and requires extended and long-term therapies. CKD patients need to choose one of these therapies to improve their quality of life. This study aims to investigate differences in the quality of life of chronic kidney disease patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis (CAPD).Design and Methods: The study design used is similar to the cross-sectional design. Therefore, in this study observations were carried out, a EQ_5D life quality questionnaire sheet was administered to respondents, and a purposive sampling method was used. The total number of respondents was 250 and consisted of 125 hemodialysis and CAPD patients each.Results: The results obtained using the Mann Whitney method was a p-value (0.515)> α (0.05). These results also included five components, namely the ability to move/walk to an acceptable degree, adequate self-care, performance of usual activities, minimal amount of pain/discomfort during hemodialysis and CAPD, and acceptable levels of anxiety/sadness.Conclusions: This research concludes that there is no difference in the quality of life between CKD patients  undergoing hemodialysis and CAPD.

Chronic Kidney Disease in Cameroon: A scoping review

2020 ◽  
Author(s):  
Jerry Brown Aseneh ◽  
Ben-Lawrence A. Kemah ◽  
Stephane Mabouna ◽  
Njang Mbeng Emmanuel ◽  
Domin Sone Majunda Ekane ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Human Immunodeficiency Virus ◽  
Kidney Disease ◽  
Scoping Review ◽  
Associated Factors ◽  
Treatment Cost ◽  
Advanced Age ◽  
High Morbidity ◽  
Immunodeficiency Virus

Abstract ObjectivesThis scoping review sought to summarize available data on the prevalence, associated factors, etiology, comorbidities, treatment, cost, and mortality of chronic kidney disease (CKD) in Cameroon.MethodsWe searched PubMed, Scopus and African Journals Online from database inception to 31 March, 2020 to identify all studies published on the prevalence, associated factors, etiology, comorbidities, treatment, cost and mortality of CKD in Cameroon.ResultsThirty studies were included. The population prevalence of CKD varied from 3-14.1% and 10.0%-14.2% in rural and urban areas, respectively. The prevalence of CKD in patients with hypertension, diabetes mellitus, and human immunodeficiency virus was 12.4-50.0%, 18.5%, and 3.0-47.2%, respectively. Hypertension (22.3-59.1%), chronic glomerulonephritis (15.8-56.2%), and diabetes mellitus (15.8-56.2%) were the most common causes of CKD. The cause was unknown in 13.5-17.0% of the cases. Advanced age, hypertension, diabetes mellitus, and obesity were frequent associated factors. Hemodialysis was the main treatment modality in patients with End Stage Renal Disease (ESRD). The monthly cost of management of non-dialyzed CKD was 163 US dollars. The one-year mortality rate of ESRD was 26.8-38.6%.ConclusionChronic kidney disease in affects about one in ten adults in the general population in Cameroon Patients with hypertension, diabetes mellitus, and human immunodeficiency virus bear the greatest burden of CKD in Cameroon. Advanced age, hypertension, diabetes mellitus, and obesity are major factors associated with CKD. Chronic kidney disease in Cameroon is associated with high morbidity and mortality and huge economic cost on the patient.

Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease

2019 ◽  
Vol 133 (17) ◽  
pp. 1857-1870 ◽  
Author(s):  
Siqi Wang ◽  
Dan Lv ◽  
Shuanghong Jiang ◽  
Jianpin Jiang ◽  
Min Liang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Renal Function ◽  
Kidney Disease ◽  
Critical Role ◽  
Short Chain Fatty Acids ◽  
Short Chain ◽  
High Morbidity ◽  
Ckd Progression ◽  
Chain Fatty Acids

Abstract Chronic kidney disease (CKD) affects 10–15% of the population worldwide, results in high morbidity and mortality, and requires costly treatment and renal replacement therapy. Glomerulosclerosis, tubulointerstitial fibrosis, and persistent intestinal flora disturbance are common in CKD. Short-chain fatty acids (SCFAs), produced by the intestinal microbiota, have been previously reported to ameliorate kidney injury; however, the specific concentrations and types that are required to improve renal function remain unknown. The present study aims to evaluate the levels of SCFAs in healthy and CKD patients, and to test the hypothesis that SCFAs play a critical role in delaying CKD progression. One hundred and twenty-seven patients with CKD and 63 healthy controls from China were enrolled in the present study. Butyrate, which is considered beneficial to humans, was almost three-times higher in healthy volunteers than that in CKD5 subjects (P=0.001). Moreover, the serum SCFA levels in controls were significantly higher than that in CKD patients (P<0.05), and the butyrate level among CKD5 patients (1.48 ± 0.60 μmol/l) was less than half of that in controls (3.44 ± 2.12 μmol/l, P<0.001). In addition, we observed an inverse correlation between butyrate level and renal function (P<0.05). A CKD rat model transplanted with microbiota obtained from CKD patients exhibited accelerated CKD progression via increased production of trimethylamine N-oxide (TMAO), which was reversed by supplementation with extra butyrate. Our results showed that SCFA levels were reduced in CKD patients and that butyrate supplementation might delay CKD progression.

scholarly journals Mid-term survival of patients with chronic kidney disease after extracorporeal membrane oxygenation

2020 ◽  
Vol 31 (5) ◽  
pp. 595-602
Author(s):  
Yueh-An Lu ◽  
Shao-Wei Chen ◽  
Cheng-Chia Lee ◽  
Victor Chien-Chia Wu ◽  
Pei-Chun Fan ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mortality Rate ◽  
Extracorporeal Membrane Oxygenation ◽  
Hospital Mortality ◽  
Subgroup Analysis ◽  
Mortality Rates ◽  
Term Survival ◽  
Membrane Oxygenation ◽  
Ecmo Treatment

Abstract OBJECTIVES Chronic kidney disease (CKD) impairs the elimination of fluids, electrolytes and metabolic wastes, which can affect the outcomes of extracorporeal membrane oxygenation (ECMO) treatment. This study aimed to elucidate the impact of CKD on in-hospital mortality and mid-term survival of adult patients who received ECMO treatment. METHODS Patients who received first-time ECMO treatment between 1 January 2003 and 31 December 2013 were included. Those with CKD were identified and matched to patients without CKD using a 1:2 ratio and were followed for 3 years. The study outcomes included in-hospital outcomes and the 3-year mortality rate. A subgroup analysis was conducted by comparing the dialytic patients with the non-dialytic CKD patients. RESULTS The study comprised 1008 CKD patients and 2016 non-CKD patients after propensity score matching. The CKD patients had higher in-hospital mortality rates [69.5% vs 62.2%; adjusted odds ratio 1.41; 95% confidence interval (CI) 1.15–1.72] than the non-CKD patients. The 3-year mortality rate was 80.4% in the CKD group and 68% in the non-CKD group (adjusted hazard ratio 1.17; 95% CI 1.06–1.28). The subgroup analysis showed that the 3-year mortality rates were 84.5% and 78.4% in the dialytic and non-dialytic patients, respectively. No difference in the 3-year mortality rate was noted between the 2 CKD subgroups (P = 0.111). CONCLUSIONS CKD was associated with increased risks of in-hospital and mid-term mortalities in patients who received ECMO treatment. Furthermore, no difference in survival was observed between the patients with end-stage renal disease and non-dialytic CKD patients.

Impact of continuous positive airway pressure (CPAP) on the respiratory capacity of chronic kidney disease patients under hemodialysis treatment

2015 ◽  
Vol 47 (6) ◽  
pp. 1011-1016 ◽  
Author(s):  
Vivian Bertoni Xavier ◽  
Renata Spósito Roxo ◽  
Luiz Antônio Miorin ◽  
Vera Lúcia dos Santos Alves ◽  
Yvoty Alves dos Santos Sens
Keyword(s):  
Chronic Kidney Disease ◽  
Continuous Positive Airway Pressure ◽  
Kidney Disease ◽  
Airway Pressure ◽  
Positive Airway Pressure ◽  
Respiratory Capacity ◽  
Hemodialysis Treatment

scholarly journals Effect of Dietary Supplements in Reducing Probability of Death for Uremic Crises in Dogs Affected by Chronic Kidney Disease (Masked RCCT)

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Andrea Zatelli ◽  
Marco Pierantozzi ◽  
Paola D'Ippolito ◽  
Mauro Bigliati ◽  
Eric Zini
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mortality Rate ◽  
Dietary Supplements ◽  
Dietary Supplementation ◽  
Phosphate Binders ◽  
Group A ◽  
Probability Of Death ◽  
Group B ◽  
To Receive

Chitosan and alkalinizing agents can decrease morbidity and mortality in humans with chronic kidney disease (CKD). Whether this holds true in dog is not known. Objective of the study was to determine whether a commercial dietary supplement containing chitosan, phosphate binders, and alkalinizing agents (Renal), compared to placebo, reduces mortality rate due to uremic crises in dogs with spontaneous CKD, fed a renal diet (RD). A masked RCCT was performed including 31 azotemic dogs with spontaneous CKD. Dogs enrolled in the study were randomly allocated to receive RD plus placebo (group A; 15 dogs) or RD plus Renal (group B; 16 dogs). During a first 4-week period, all dogs were fed an RD and then randomized and clinically evaluated up to 44 weeks. The effects of dietary supplements on mortality rate due to uremic crises were assessed. At 44 weeks, compared to group A, dogs in group B had approximately 50% lower mortality rate due to uremic crises (P=0.015). Dietary supplementation with chitosan, phosphate binders, and alkalinizing agents, along with an RD, is beneficial in reducing mortality rate in dogs with spontaneous CKD.

scholarly journals Data Analysis on Chronic Kidney Disease Prognosis

2020 ◽  
Vol 8 (6S) ◽  
pp. 130-132
Keyword(s):  
Machine Learning ◽  
Chronic Kidney Disease ◽  
Data Analysis ◽  
Kidney Disease ◽  
Kidney Diseases ◽  
Chronic Kidney Diseases ◽  
Optimum Result ◽  
Disease Prognosis

We have taken our dataset from UCI Machine Learning Repository. Our study is about Chronic Kidney Diseases based on 24 input attributes to produce one output attribute i.e. a patient is suffering from chronic kidney disease or not. We have used three major attributes in our study i.e. PCV, RBCC and Hemoglobin with respect to Age for optimum result. These attributes play major role in our study.

scholarly journals To assess the quality of life in patients with chronic kidney disease undergoing hemodialysis at a satellite clinic, comparing patients from a median low-income household with patients from median middle- and upper-income households: cross-sectional study

2020 ◽  
Author(s):  
UBIRACE FERNANDO ELIHIMAS JUNIOR ◽  
Marília Costa Aranha Forte ◽  
Alexandre Holanda Cavalcanti Pinto ◽  
Eduardo Eriko Tenório de França ◽  
Jamila Pinho Couto ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Low Income ◽  
Physical Functioning ◽  
General Health ◽  
Positive Association ◽  
Hemodialysis Treatment ◽  
Sf 36

Abstract Background: Chronic kidney disease is a financial challenge for global public health due to rising costs, a poorer quality of life. Globally, there has been an increase in the number of diabetic, hypertensive and obese patients, with a tendency to rise as life expectancy increases. Objective: To assess the quality of life of patients with chronic kidney disease on hemodialysis at a satellite clinic in Recife, Northeast Brazil, and comparing low-income patients funded by the national healthcare system with middle- and higher-income patients funded by private health insurance. Methods: The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) was applied, together with a complementary interview with socio-demographic data for all patients at a conventional hemodialysis clinic. All patients were submitted to the same hemodialysis protocol, 4 hours and 10 minutes, high flow biocompatible membranes with high mass transfer coefficient and an adequacy of Kt/V ≥1.2. Results: The poorest quality of life scores with the SF-36 were related to physical functioning and pain. The best scores were attributed to mental health, social functioning, general health and vitality with no differences between the household incomes. There was a positive association between education, role-emotional and physical functioning. Longer hemodialysis treatment times demonstrated a positive association with aspects of general health. Patients who had undergone hemodialysis between one and five years presented better quality of life scores with the SF-36. Conclusions: Hemodialysis treatment negatively influences the quality of life of patients with chronic kidney disease. Education seems to help patients to better understand and accept treatment, by raising the scores of the physical functioning and role-physical. The first year of hemodialysis seems to exert a more negative influence on the quality of life. Among all patients, pain and physical aspects seem to be the critical points, regardless of social class or income.

scholarly journals Lymphocytes: Versatile Participants in Acute Kidney Injury and Progression to Chronic Kidney Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Chujin Cao ◽  
Ying Yao ◽  
Rui Zeng
Keyword(s):  
Chronic Kidney Disease ◽  
Acute Kidney Injury ◽  
Kidney Disease ◽  
Renal Injury ◽  
Renal Fibrosis ◽  
Kidney Injury ◽  
Renal Parenchyma ◽  
Health Concern ◽  
High Morbidity ◽  
Parenchyma Cells

Background: Acute kidney injury (AKI) remains a major global public health concern due to its high morbidity and mortality. The progression from AKI to chronic kidney disease (CKD) makes it a scientific problem to be solved. However, it is with lack of effective treatments.Summary: Both innate and adaptive immune systems participate in the inflammatory process during AKI, and excessive or dysregulated immune responses play a pathogenic role in renal fibrosis, which is an important hallmark of CKD. Studies on the pathogenesis of AKI and CKD have clarified that renal injury induces the production of various chemokines by renal parenchyma cells or resident immune cells, which recruits multiple-subtype lymphocytes in circulation. Some infiltrated lymphocytes exacerbate injury by proinflammatory cytokine production, cytotoxicity, and interaction with renal resident cells, which constructs the inflammatory environment and induces further injury, even death of renal parenchyma cells. Others promote tissue repair by producing protective cytokines. In this review, we outline the diversity of these lymphocytes and their mechanisms to regulate the whole pathogenic stages of AKI and CKD; discuss the chronological responses and the plasticity of lymphocytes related to AKI and CKD progression; and introduce the potential therapies targeting lymphocytes of AKI and CKD, including the interventions of chemokines, cytokines, and lymphocyte frequency regulation in vivo, adaptive transfer of ex-expanded lymphocytes, and the treatments of gut microbiota or metabolite regulations based on gut-kidney axis.Key Message: In the process of AKI and CKD, T helper (Th) cells, innate, and innate-like lymphocytes exert mainly pathogenic roles, while double-negative T (DNT) cells and regulatory T cells (Tregs) are confirmed to be protective. Understanding the mechanisms by which lymphocytes mediate renal injury and renal fibrosis is necessary to promote the development of specific therapeutic strategies to protect from AKI and prevent the progression of CKD.

Sign in / Sign up

Export Citation Format

Share Document